COLOGNE, Germany and NEUMÜNSTER, Germany, Feb. 23, 2024 (GLOBE NEWSWIRE) --
Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), a global leader in
cannabis research, cultivation, production, and distribution, today announced
that its medical cannabis division, Tilray Medical, the global leader in medical
cannabis, enthusiastically welcomes the opening of the German medical cannabis
market and the positive paradigm shift in German drug policy. Today's landmark
passage of the German Medical Cannabis Act represents a significant step forward
and puts public health in the spotlight while providing patients with easier
access to high-quality cannabis medicines produced in Germany.
Tilray Medical's Chief Strategy Officer and Head of International Denise Faltischek comments: "The decision to open up the previously limited German medical cannabis market is an important step that will allow patients and physicians to explore effective treatment options tailored to individual needs. Facilitating access to the highest quality cannabis medicines through the new Medical Cannabis Act, produced in Germany, will help to improve patient care and
provide patients with a wider range of treatment options."
Tilray Medical looks forward to working with numerous partners to utilize the production capacity at Tilray's state of the art Neumünster site, which is one of only three cannabis cultivation facilities located in Germany, in order to ensure that patients have improved access to the highest quality cannabis medicines grown in Germany.
As a leader in the field of medical cannabis research and production, Tilray Medical strongly believes that these developments will have a positive impact on
the health and well-being of many patients in Germany. We look forward to exploring the path opended by the German government and all stakeholders in promoting improved access to medical cannabis, and the opportunity to optimize care for our patients.
About Tilray Medical?
Tilray Medical is dedicated to transforming lives and fostering dignity for
patients in need through safe and reliable access to a global portfolio of
medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios, and
Navcora. Tilray Medical grew from being one of the first companies to become an
approved licensed producer of medical cannabis in Canada to building the first
GMP-certified cannabis production facilities in Europe, first in Portugal and
later in Germany. Today, Tilray Medical is one of the biggest suppliers of
medical cannabis brands to patients, physicians, hospitals, pharmacies,
researchers, and governments, in over 20 countries and across five continents.
Further information can also be found at www.tilraymedical.de
(https://tilraymedical.de/)
About Tilray Brands
Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY), is a leading global
cannabis lifestyle and consumer packaged goods company with operations in
Canada, the United States, Europe, Australia, and Latin America that is changing
people's lives for the better - one person at a time - by inspiring and
empowering a worldwide community to live their very best life, enhanced by
moments of connection and wellbeing. Tilray's mission is to be the most
responsible, trusted and market leading cannabis consumer products company in
the world with a portfolio of innovative, high-quality, and beloved brands that
address the needs of the consumers, customers, and patients we serve. A pioneer
in cannabis research, cultivation, and distribution, Tilray's unprecedented
production platform supports over 20 brands in over 20 countries, including
comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit, Tilray.com
(http://www.tilray.com) and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts
constitute forward-looking information or forward-looking statements (together,
"forward-looking statements") under Canadian securities laws and within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, that are intended to be
subject to the "safe harbor" created by those sections and other applicable
laws. Forward-looking statements can be identified by words such as "forecast,"
"future," "should," "could," "enable," "potential," "contemplate," "believe,"
"anticipate," "estimate," "plan," "expect," "intend," "may," "project," "will,"
"would" and the negative of these terms or similar expressions, although not all
forward-looking statements contain these identifying words. Certain material
factors, estimates, goals, projections, or assumptions were used in drawing the
conclusions contained in the forward-looking statements throughout this
communication. Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current expectations
concerning, among other things, the Company's ability to commercialize new and
innovative products worldwide. Many factors could cause actual results,
performance, or achievement to be materially different from any forward-looking
statements, and other risks and uncertainties not presently known to the Company
or that the Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking statements
contained herein. For a more detailed discussion of these risks and other
factors, see the most recently filed annual information form of Tilray and the
Annual Report on Form 10-K (and other periodic reports filed with the SEC) of
Tilray made with the SEC and available on EDGAR. The forward-looking statements
included in this communication are made as of the date of this communication and
the Company does not undertake any obligation to publicly update such forward-
looking statements to reflect new information, subsequent events, or otherwise
unless required by applicable securities laws.
For further information:
Media: Berrin Noorata, news@tilray.com (mailto:news@tilray.com)
Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com (mailto:Raphael.Gross@icrinc.com)
Â